A Two Part Clinical Trial Assessing the Safety, Tolerability, Immunogenicity and Protective Efficacy of NMRC-M3V-Ad-PfCA, a Multivalent, Adenovirus-Vectored Plasmodium Falciparum Malaria Vaccine, in Healthy, Malaria-Naive Adults
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Malaria vaccine (Primary)
- Indications Falciparum malaria
- Focus Adverse reactions; Therapeutic Use
- 30 Jul 2020 Status changed from active, no longer recruiting to completed.
- 06 May 2020 Planned End Date changed from 1 Dec 2019 to 30 Jun 2020.
- 17 Sep 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.